Breast cancer patients with estrogen receptor mutations may benefit from early switch to fulvestrant/palbociclib
Progress on England’s mental health services ‘requires improvement,’ finds panel
9 December 2021Violence increased most in marginalized neighborhoods early in the COVID-19 pandemic
9 December 2021Breast cancer patients with estrogen receptor mutations may benefit from early switch to fulvestrant/palbociclib
Among patients with hormone receptor-positive breast cancer treated with an aromatase inhibitor plus palbociclib (Ibrance), those who displayed a rising ESR1 mutation detected in their blood before disease progression doubled their median progression-free survival following a switch to fulvestrant (Faslodex) plus palbociclib, according to results from the phase III PADA-1 clinical trial presented at the San Antonio Breast Cancer Symposium, held December 7-10, 2021.
